637330-35-9

Upstream product

• 69739-34-0 t-butyldimethylsiyl triflate 
• 637330-34-8 methyl [2-nitro-4-(O-tert-butyldiphenylsilylmethyl)phenyl-β-D-glucopyranosid]uronate 
• 637330-32-6 methyl [2-nitro-4-(hydroxymethyl)phenyl-β-D-glucopyranosid]uronate 
• 148579-94-6 (25,3R,45,55,65)-2-(4-(hydroxymethyl)-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 148579-93-5 (2S,3R,4S,5S,6S)-2-(4-formyl-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 

Downstream Products

• 637330-36-0 benzyl {[2-nitro-4-(O-tert-butyldiphenylsilylmethyl)phenyl]-2,3,4-tri-(O-tert-butyldimethylsilyl)-β-D-glucopyranosid}uronate 
• 637330-39-3 N,N'-dimethyl-N-benzyl-[4-(2,3,4-tri-O-tert-butyldimethylsilyl-β-D-glucopyranosyl)uronate-3-nitrobenzoyloxycarbonyl]-N'-(tert-butoxycarbonyl)ethylenediamine 
• 637330-41-7 N,N'-dimethyl-N-benzyl-[4-(2,3,4-tri-O-tert-butyldimethylsilyl-β-D-glucopyranosyl)uronate-3-nitrobenzoyloxycarbonyl]ethylenediamine carbamoyl chloride 
• 637330-38-2 benzyl [(2-nitro-4-(4-nitrophenoxycarbonyloxymethyl)phenoxy)-2,3,4-tri-(O-tert-butyldimethylsilyl)-β-D-glucopyranosid]uronate 
• 637330-37-1 benzyl [(2-nitro-4-hydroxymethylphenyl)-2,3,4-tri-(O-tert-butyldimethylsilyl)-β-D-glucopyranosid]uronate 

Relevant academic research and scientific papers

A new paclitaxel prodrug for use in ADEPT strategy

A new paclitaxel prodrug intended for use in Antibody-Directed Prodrug Therapy (ADEPT) or Prodrug Monotherapy (PMT) has been prepared. This prodrug was originally designed to be activated into the drug by human β-glucuronidase. In order to enhance the liberation rate of paclitaxel, an elongated spacer system including a nitro-aromatic derivative and a N,N′-methylethylenediamine was incorporated between the sugar moiety and the drug. Indeed, this new prodrug proved to be activated significantly faster than a former paclitaxel prodrug containing a conventional spacer.